ATORX — Alligator Bioscience AB Share Price
Last trade - 00:00- SEK163.53m
- SEK142.79m
- SEK57.77m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.83 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -396.66% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 4.35 | 12.94 | 35.7 | 58.11 | 57.77 | 93 | 119 | 67.68% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Alligator Bioscience AB is a Sweden-based biotechnology Company that develops antibody-based drugs for cancer treatment. The Company specializes in the development of tumor-targeted immunotherapies, in particular agonist mono- and bispecific antibodies, and is active in the early stages of drug development, from concept to phase II clinical trials. Alligator’s pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its technology platform, Neo-X-Prime, with MacroGenics Inc. and drug candidates based on the RUBY bispecific platform with Orion Corporation. Its licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. The Company operates domestically.
Directors
- Malin Carlsson CEO
- Soren Bregenholt CEO
- Marie Svensson CFO (57)
- Christina Furebring SVP (55)
- Peter Ellmark CSO (48)
- Gayle Mills OTH (67)
- Christina Reimer OTH (49)
- Laura Von Schantz DRC (37)
- Graham Dixon IND (59)
- Anders Ekblom IND (66)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 21st, 2000
- Public Since
- November 23rd, 2016
- No. of Shareholders
- 11,891
- No. of Employees
- 45
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 29,646,577.65
- Address
- SCHEELEVAGEN 2 byggnad 401, LUND, 223 63
- Web
- https://alligatorbioscience.se/
- Phone
- +46 465408200
- Contact
- Guillaume Van Renterghem
- Auditors
- Ohrlings PricewaterhouseCoopers AB
Latest News for ATORX
Upcoming Events for ATORX
Q1 2025 Alligator Bioscience AB Earnings Release
Alligator Bioscience AB Annual Shareholders Meeting
Q2 2025 Alligator Bioscience AB Earnings Release
Similar to ATORX
2cureX AB
OMX Nordic Exchange Stockholm
Acousort AB
OMX Nordic Exchange Stockholm
Active Biotech AB publ
OMX Nordic Exchange Stockholm
AlzeCure Pharma AB
OMX Nordic Exchange Stockholm
Alzinova AB
OMX Nordic Exchange Stockholm
FAQ
As of Today at 19:11 UTC, shares in Alligator Bioscience AB are trading at SEK5.52. This share price information is delayed by 15 minutes.
Shares in Alligator Bioscience AB last closed at SEK5.52 and the price had moved by -93.77% over the past 365 days. In terms of relative price strength the Alligator Bioscience AB share price has underperformed the FTSE Global All Cap Index by -93.88% over the past year.
The overall consensus recommendation for Alligator Bioscience AB is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreAlligator Bioscience AB does not currently pay a dividend.
Alligator Bioscience AB does not currently pay a dividend.
Alligator Bioscience AB does not currently pay a dividend.
To buy shares in Alligator Bioscience AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of SEK5.52, shares in Alligator Bioscience AB had a market capitalisation of SEK163.53m.
Here are the trading details for Alligator Bioscience AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: ATORX
Based on an overall assessment of its quality, value and momentum Alligator Bioscience AB is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Alligator Bioscience AB is SEK30.00. That is 443.87% above the last closing price of SEK5.52.
Analysts covering Alligator Bioscience AB currently have a consensus Earnings Per Share (EPS) forecast of -SEK0.08 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Alligator Bioscience AB. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -94.7%.
As of the last closing price of SEK5.52, shares in Alligator Bioscience AB were trading -91.11% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Alligator Bioscience AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK5.52.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Alligator Bioscience AB's management team is headed by:
- Malin Carlsson - CEO
- Soren Bregenholt - CEO
- Marie Svensson - CFO
- Christina Furebring - SVP
- Peter Ellmark - CSO
- Gayle Mills - OTH
- Christina Reimer - OTH
- Laura Von Schantz - DRC
- Graham Dixon - IND
- Anders Ekblom - IND